Rapid and label-free isolation of tumour cells from the urine of patients with localised prostate cancer using inertial microfluidics

Rzhevskiy, AS; Bazaz, SR; Ding, L; Kapitannikova, A; Sayyadi, N; Campbell, D; Walsh, B; Gillatt, D; Warkiani, ME; Zvyagin, AV

Rapid and label-free isolation of tumour cells from the urine of patients with localised prostate cancer using inertial microfluidics

Rzhevskiy, AS Bazaz, SR Ding, L Kapitannikova, A Sayyadi, N

Campbell, D Walsh, B Gillatt, D Warkiani, ME

Zvyagin, AV

Permalink

Publication Type:: Journal Article
Citation:: Cancers, 2020, 12 (1)
Issue Date:: 2020-01-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published VersionAdobe PDF (2.72 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Rzhevskiy, AS	en_US
dc.contributor.author	Bazaz, SR	en_US
dc.contributor.author	Ding, L	en_US
dc.contributor.author	Kapitannikova, A	en_US
dc.contributor.author	Sayyadi, N https://orcid.org/0000-0002-0044-2170	en_US
dc.contributor.author	Campbell, D	en_US
dc.contributor.author	Walsh, B	en_US
dc.contributor.author	Gillatt, D	en_US
dc.contributor.author	Warkiani, ME https://orcid.org/0000-0002-4184-1944	en_US
dc.contributor.author	Zvyagin, AV	en_US
dc.date.available	2019-12-24	en_US
dc.date.issued	2020-01-01	en_US
dc.identifier.citation	Cancers, 2020, 12 (1)	en_US
dc.identifier.uri	http://hdl.handle.net/10453/138232
dc.description.abstract	© 2019 by the authors. Licensee MDPI, Basel, Switzerland. During the last decade, isolation of circulating tumour cells via blood liquid biopsy of prostate cancer (PCa) has attracted significant attention as an alternative, or substitute, to conventional diagnostic tests. However, it was previously determined that localised forms of PCa shed a small number of cancer cells into the bloodstream, and a large volume of blood is required just for a single test, which is impractical. To address this issue, urine has been used as an alternative to blood for liquid biopsy as a truly non-invasive, patient-friendly test. To this end, we developed a spiral microfluidic chip capable of isolating PCa cells from the urine of PCa patients. Potential clinical utility of the chip was demonstrated using anti-Glypican-1 (GPC-1) antibody as a model of the primary antibody in immunofluorescent assay for identification and detection of the collected tumour cells. The microchannel device was first evaluated using DU-145 cells in a diluted Dulbecco’s phosphate-buffered saline sample, where it demonstrated >85 (±6) % efficiency. The microchannel proved to be functional in at least 79% of cases for capturing GPC1+ putative tumour cells from the urine of patients with localised PCa. More importantly, a correlation was found between the amount of the captured GPC1+ cells and crucial diagnostic and prognostic parameter of localised PCa—Gleason score. Thus, the technique demonstrated promise for further assessment of its diagnostic value in PCa detection, diagnosis, and prognosis.	en_US
dc.relation.ispartof	Cancers	en_US
dc.relation.isbasedon	10.3390/cancers12010081	en_US
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Rapid and label-free isolation of tumour cells from the urine of patients with localised prostate cancer using inertial microfluidics	en_US
dc.type	Journal Article
utslib.citation.volume	1	en_US
utslib.citation.volume	12	en_US
utslib.for	1112 Oncology and Carcinogenesis	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
utslib.copyright.status	open_access	*
pubs.issue	1	en_US
pubs.publication-status	Published	en_US
pubs.volume	12	en_US

Abstract:

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. During the last decade, isolation of circulating tumour cells via blood liquid biopsy of prostate cancer (PCa) has attracted significant attention as an alternative, or substitute, to conventional diagnostic tests. However, it was previously determined that localised forms of PCa shed a small number of cancer cells into the bloodstream, and a large volume of blood is required just for a single test, which is impractical. To address this issue, urine has been used as an alternative to blood for liquid biopsy as a truly non-invasive, patient-friendly test. To this end, we developed a spiral microfluidic chip capable of isolating PCa cells from the urine of PCa patients. Potential clinical utility of the chip was demonstrated using anti-Glypican-1 (GPC-1) antibody as a model of the primary antibody in immunofluorescent assay for identification and detection of the collected tumour cells. The microchannel device was first evaluated using DU-145 cells in a diluted Dulbecco’s phosphate-buffered saline sample, where it demonstrated >85 (±6) % efficiency. The microchannel proved to be functional in at least 79% of cases for capturing GPC1+ putative tumour cells from the urine of patients with localised PCa. More importantly, a correlation was found between the amount of the captured GPC1+ cells and crucial diagnostic and prognostic parameter of localised PCa—Gleason score. Thus, the technique demonstrated promise for further assessment of its diagnostic value in PCa detection, diagnosis, and prognosis.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/138232